BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Head and neck cancer AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Diagnosis
81 results:

  • 1. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers.
    Mestiri S; El-Ella DMA; Fernandes Q; Bedhiafi T; Almoghrabi S; Akbar S; Inchakalody V; Assami L; Anwar S; Uddin S; Gul ARZ; Al-Muftah M; Merhi M; Raza A; Dermime S
    Biomed Pharmacother; 2024 Feb; 171():116095. PubMed ID: 38183744
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy.
    Shi M; Sun D; Ma X; Liu J; Zhang Y; Liu T; Chen X; Mo S; Zhao Y; Zhang L
    Hum Vaccin Immunother; 2023 Dec; 19(3):2294579. PubMed ID: 38111107
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Case Report: Toripalimab: a novel immune checkpoint inhibitor in advanced nasopharyngeal carcinoma and severe immune-related colitis.
    Luo C; Chen H; Wu H; Liu Y; Li G; Lun W
    Front Immunol; 2023; 14():1298902. PubMed ID: 38077371
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Immune checkpoint inhibitor induced colitis and arthritis: A case report.
    Xie RX; Xue YB; Ci XY; Zhang MJ
    Medicine (Baltimore); 2023 Dec; 102(49):e36334. PubMed ID: 38065892
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Pneumatosis intestinalis in cancer patients who received immune checkpoint inhibitors.
    Sperling G; Shatila M; Varatharajalu K; Lu Y; Altan M; Zhou Y; Zhao D; De Toni EN; Török HP; Schneider BJ; Khan A; Thomas AS; Zhang HC; Shafi MA; Wang Y
    J Cancer Res Clin Oncol; 2023 Dec; 149(19):17597-17605. PubMed ID: 37917197
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Current and Emerging Role of Monoclonal Antibody-Based First-Line Treatment in Advanced Gastro-Esophageal and Gastric cancer.
    Désilets A; Elkhoury R; Gebai A; Tehfe M
    Curr Oncol; 2023 Oct; 30(10):9304-9316. PubMed ID: 37887572
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Modern diagnostics and treatment of Merkel cell carcinoma.
    Weilandt J; Peitsch WK
    J Dtsch Dermatol Ges; 2023 Dec; 21(12):1524-1546. PubMed ID: 37875785
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Encephalitis in a patient with hypopharynx cancer treated with immune checkpoint inhibitors and radiotherapy: a case report and review of the literature.
    Kang Y; Zhen H; Ma N; Zhao H; Cao B
    J Cancer Res Clin Oncol; 2023 Nov; 149(17):16239-16246. PubMed ID: 37676267
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Pulmonary sarcoidosis-like reactions induced by sintilimab in esophageal cancer: A case report.
    Li H; Mu F; Zou B; Wang L
    Medicine (Baltimore); 2023 Aug; 102(31):e34432. PubMed ID: 37543824
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Acute kidney injury in patients with cancer receiving anti-pd-1/PD-L1 antibodies: incidence, risk factors, and prognosis.
    Lou Q; Gong J; Ye B; Yu R; Bu S; Li Y; Zhu B; Shao L
    Ren Fail; 2023 Dec; 45(1):2238823. PubMed ID: 37491871
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Prognosis in stage II melanoma of the head and neck depends on the histological subtype.
    Jasper S; Keim U; Leiter U; Amaral T; Flatz L; Forschner A
    J Dtsch Dermatol Ges; 2023 Oct; 21(10):1137-1146. PubMed ID: 37485634
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Comparison of Clinical Outcomes, Pathologic Characteristics, and Immune-Related Features of Postradiation vs Sporadic Oral Cavity Squamous Cell Carcinoma.
    Chow JCH; Cheuk W; Cho WCS; Wong CF; Au DWY; Tam AHP; Wong RCW; Chan JCH; Law SCC; Ngan RKC; Wong KH; Cheung KM
    JAMA Netw Open; 2023 Jul; 6(7):e2323890. PubMed ID: 37459093
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Neoadjuvant pd-1/PD-L1 axis blockade for patients with head and neck squamous cell carcinoma.
    Huang S; Xiong C; Tan K
    Am J Otolaryngol; 2023; 44(6):103985. PubMed ID: 37442083
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Pulmonary adenoid cystic carcinoma: molecular characteristics and literature review.
    Chen Z; Jiang J; Fan Y; Lu H
    Diagn Pathol; 2023 May; 18(1):65. PubMed ID: 37198615
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. PD-L1 and MCL-1 markers and the relationship with prognostic characteristics of differentiated thyroid carcinoma.
    Zantut-Wittmann DE; Barreto IS; Laus AC; Moreno DA; Moma CA; Maia FFR; Assumpção LVMD; Reis RM
    Mol Cell Endocrinol; 2023 Jun; 570():111931. PubMed ID: 37072108
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. An immune checkpoint-based signature predicts prognosis and chemotherapy response for patients with small cell lung cancer.
    Wang L; Wu P; Shen Z; Yu Q; Zhang Y; Ye F; Chen K; Zhao J
    Int Immunopharmacol; 2023 Apr; 117():109827. PubMed ID: 36989973
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. An epulis-like camrelizumab related reactive cutaneous capillary endothelial proliferation (RCCEP) in the oral cavity: A case report.
    Hua Y; Huang X; Li C; Gao N
    Oral Oncol; 2023 May; 140():106369. PubMed ID: 36989963
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Single-cell transcriptomic analysis deciphers key transitional signatures associated with oncogenic evolution in human intramucosal oesophageal squamous cell carcinoma.
    Liu XY; Liu YB; Xu JC; Zhang YF; Ruan YY; Zhao Y; Wu LF; Hu JW; Zhang Z; He MJ; Chen TY; Xu XY; Zhang JW; Zhang YQ; Zhou PH
    Clin Transl Med; 2023 Mar; 13(3):e1203. PubMed ID: 36855810
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Immune-related adverse events after immune checkpoint inhibitor exposure in adult cancer patients with pre-existing autoimmune diseases.
    Pizuorno Machado A; Shatila M; Liu C; Wang J; Altan M; Zhang HC; Thomas A; Wang Y
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6341-6350. PubMed ID: 36752908
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to pd-1 and PD-L1 inhibitors.
    Thomas AR; Liu C; Tong YT; Tan D; Altan M; Siddiqui BA; Shatila M; Khan A; Thomas AS; Wang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5429-5436. PubMed ID: 36451045
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.